Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

In reply to the Letter to Editor regarding "Comment on "Development and validation of a predictive model for profiling antibiotic resistance phenotypes of Acinetobacter baumannii strains via clinical MALDI-TOF mass spectra: A multicenter study".

International journal of antimicrobial agents·2026
Same author

<i>Dendrobium devonum</i> juice modulates aroma formation in coffee cherry husks processing: insights into key pathways and flavour enhancement.

Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment·2026
Same author

Retinal vascular features enhance short-term prediction of delivery in hypertensive disorders of pregnancy.

Journal of hypertension·2026
Same author

Multilayer microcapsules improved the tolerance to adverse conditions of Pseudomonas aeruginosa A14 and biocontrol effect against cabbage Fusarium wilt.

Pest management science·2026
Same author

Lipase-Catalyzed Enantioselective Resolution of Chiral Pesticides and Herbicides: Advances in Biocatalysis and Enzyme Engineering.

Journal of agricultural and food chemistry·2026
Same author

A National Survey on Critically Ill Obstetric Patients Care Centers.

Maternal-fetal medicine (Wolters Kluwer Health, Inc.)·2026

相关实验视频

Updated: Sep 10, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K

优化模块化抗FLAGCAR T细胞用于固体瘤治疗

Xiaomeng Zhang1,2, Rachel Xu1,2, Dmitry Zorin1

  • 1Cancer Immunology Program Peter MacCallum Cancer Centre Melbourne VIC Australia.

Clinical & translational immunology
|August 25, 2025
PubMed
概括

设计了一种抗FLAG CAR T细胞疗法来克服瘤的挑战. 优化的CAR-T细胞显示减少疲劳并有效抑制瘤生长,为癌症治疗提供灵活的平台.

关键词:
标志国家在HER2嵌合式抗原受体固体癌症标志性信号

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

791
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.6K

相关实验视频

Last Updated: Sep 10, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

791
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.6K

科学领域:

  • 免疫疗法
  • 癌症学
  • 分子工程

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法对B细胞恶性瘤有效,但在固体瘤中面临挑战,包括抗原逃逸和异质性.
  • 目前CAR T细胞的局限性阻碍了其在治疗固体癌症等复杂疾病中的更广泛应用.

研究的目的:

  • 开发一种新的抗FLAG CAR T细胞系统,以灵活地向固体瘤.
  • 设计一个模块化的CART细胞平台,能够使用二次FLAG标记的试剂进行适应性癌症治疗.

主要方法:

  • 设计了一个人性化的反旗汽车, 优化其结构以减轻增强信号和疲劳.
  • 在使用FLAG工程瘤细胞和FLAG标记的二次向试剂的固体瘤小鼠模型中评估治疗效果.

主要成果:

  • 最初的反FLAG CAR构造显示出功能性活动,但受到增强信号和疲劳的影响.
  • 结构优化显著降低了CAR T细胞的耗尽,提高了其持续性和功能.
  • 在临床前模型中,优化的CAR T细胞显示有效抑制瘤生长.

结论:

  • 为了最大限度地减少T细胞耗尽和最大限度地提高治疗效果,CAR的设计至关重要.
  • 这种模块化的CAR T细胞平台显示出在固体瘤中克服抗原异质和免疫逃避的潜力.
  • 反FLAG CAR系统为下一代癌症免疫疗法提供了灵活和可适应的策略.